Insider trade

Director received an award of 231 ABT derivative securities

Traded Jun 30, 2026 · Filed Jul 1, 2026

Abbott LaboratoriesABT

231
Derivative units · @ $90.74

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jun 30, 2026
Reporting period: Not applicable
Filed with the SEC: Jul 1, 2026

DirectorGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001306119-26-000006
Filed / recorded

Jul 1, 2026, 9:28 PM UTC

Added to OQRO

Oct 2, 2026, 12:26 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

ABBOTT LABORATORIES

Issuer CIK

1800

Ticker

ABT

Reporting person

Kevin T Conroy

Relationship

Director

Security

Stock Equivalent Units

Table

Derivative (Table II)

Transaction date

Jun 30, 2026

Transaction code

A

Shares / units

231

Price per share

$90.74

Acquired / disposed

Acquired (A)

Shares owned after

231

Ownership form

Direct

Amendment

No

Footnotes from the filing

Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock.